Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TargetTau-1
NCT06268886Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of PRX005 in Alzheimer's disease (AD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change from baseline in brain tau deposition as measured by tau positron emission tomography (PET) at 76 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
PRX005
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06268886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268886.